The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug believed to partially inhibit fatty acid oxidation, increased treadmill exercise performance; however, its long-term efficacy and safety have not been studied in combination with beta-blockers or calcium antagonists in a large patient population with severe chronic angina. OBJECTIVES: To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension. DESIGN, SETTING, AND PATIENTS: A randomized, 3-group parallel, double-blind, placebo-controlled trial of 823 eligible adults with symptomatic chronic angina who were randomly assigned to receive placebo or 1 of 2 doses of ranolazine. Patients treated at the 118 participating ambulatory outpatient settings in several countries were enrolled in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial from July 1999 to August 2001 and followed up through October 31, 2002. INTERVENTION: Patients received twice-daily placebo or 750 mg or 1000 mg of ranolazine. Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment. MAIN OUTCOME MEASURES: Change in exercise duration, time to onset of angina, time to onset of ischemia, nitroglycerin use, and number of angina attacks. RESULTS: Trough exercise duration increased by 115.6 seconds from baseline in both ranolazine groups (pooled) vs 91.7 seconds in the placebo group (P =.01). The times to angina and to electrocardiographic ischemia also increased in the ranolazine groups, at peak more than at trough. The increases did not depend on changes in blood pressure, heart rate, or background antianginal therapy and persisted throughout 12 weeks. Ranolazine reduced angina attacks and nitroglycerin use by about 1 per week vs placebo (P<.02). Survival of 750 patients taking ranolazine during the CARISA trial or its associated long-term open-label study was 98.4% in the first year and 95.9% in the second year. CONCLUSION: Twice-daily doses of ranolazine increased exercise capacity and provided additional antianginal relief to symptomatic patients with severe chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adverse, long-term survival consequences over 1 to 2 years of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Gibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., Deedwania, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,689
Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease
Serruys, P. W., Unger, F., Sousa, J. E., Jatene, A., Bonnier, H. J. R. M., Schönberger, J. P. A. M., Buller, N., Bonser, R., van den Brand, M. J. B., van Herwerden, L. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441502 · Cited by 1,114
Exercise Treadmill Score for Predicting Prognosis in Coronary Artery Disease
MARK, D. B., HLATKY, M. A., HARRELL, F. E., LEE, K. L., CALIFF, R. M., & PRYOR, D. B. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-793 · Cited by 671
Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts
McCormack, J. G., Barr, R. L., Wolff, A. A., & Lopaschuk, G. D. (1996) · Circulation · doi:10.1161/01.cir.93.1.135 · Cited by 291
Self-citationMultiple testing in clinical trials
Bauer, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100609 · Cited by 241
Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance
Lawrence Gould, A., & Shih, W. J. (1992) · Communications in Statistics - Theory and Methods · doi:10.1080/03610929208830947 · Cited by 239
Value of exercise treadmill testing in women
Alexander, K. P., Shaw, L. J., DeLong, E. R., Mark, D. B., & Peterson, E. D. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00451-3 · Cited by 233
Hung, J., Lamb, I. H., Connolly, S. J., Jutzy, K. R., Goris, M. L., & Schroeder, J. S. (1983) · Circulation · doi:10.1161/01.cir.68.3.560 · Cited by 158
Fox, K. M., Mulcahy, D., Findlay, I., Ford, I., Dargie, H. J., & on behalf of the TIBET study group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014699 · Cited by 150
Cited by
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Authors/Task Force Members (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,336
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000134 · Cited by 1,059
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., Cordeiro, J. M., & Thomas, G. (2004) · Circulation · doi:10.1161/01.cir.0000139333.83620.5d · Cited by 675
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Chaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567
Self-citationScirica, B. M., Morrow, D. A., Hod, H., Murphy, S. A., Belardinelli, L., Hedgepeth, C. M., Molhoek, P., Verheugt, F. W. A., Gersh, B. J., McCabe, C. H., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.724880 · Cited by 445
Loss of Metabolic Flexibility in the Failing Heart
Karwi, Q. G., Uddin, G. M., Ho, K. L., & Lopaschuk, G. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00068 · Cited by 442
Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.015 · Cited by 400
Qaseem, A., Fihn, S. D., Williams, S., Dallas, P., Owens, D. K., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00010 · Cited by 393
Belardinelli, L., Shryock, J. C., & Fraser, H. (2006) · Heart · doi:10.1136/hrt.2005.078790 · Cited by 386
Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine
Stone, P. H., Gratsiansky, N. A., Blokhin, A., Huang, I.-Z., & Meng, L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.044 · Cited by 355
Tardif, J.-C., Ponikowski, P., Kahan, T., & for the ASSOCIATE study Investigators (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn571 · Cited by 340
Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 333
Chronic Coronary Artery Disease: Diagnosis and Management
Cassar, A., Holmes, D. R., Rihal, C. S., & Gersh, B. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0391 · Cited by 324
van Ramshorst, J., Bax, J. J., Beeres, S. L. M. A., Dibbets-Schneider, P., Roes, S. D., Stokkel, M. P. M., de Roos, A., Fibbe, W. E., Zwaginga, J. J., Boersma, E., et al. (2009) · JAMA · doi:10.1001/jama.2009.685 · Cited by 300
Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions
Chaitman, B. R. (2006) · Circulation · doi:10.1161/circulationaha.105.597500 · Cited by 294
Self-citationBlinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M. P., Zamora, V., Smith, G., Crumb, W. J., Pang, L., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw200 · Cited by 272
UNDROVINAS, A. I., BELARDINELLI, L., UNDROVINAS, N. A., & SABBAH, H. N. (2006) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2006.00401.x · Cited by 266
Sossalla, S., Wagner, S., Rasenack, E. C. L., Ruff, H., Weber, S. L., Schöndube, F. A., Tirilomis, T., Tenderich, G., Hasenfuss, G., Belardinelli, L., et al. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.006 · Cited by 262
Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina
Kosiborod, M., Arnold, S. V., Spertus, J. A., McGuire, D. K., Li, Y., Yue, P., Ben-Yehuda, O., Katz, A., Jones, P. G., Olmsted, A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.011 · Cited by 205
Self-citationEfficacy of Ranolazine in Patients With Chronic Angina
Wilson, S. R., Scirica, B. M., Braunwald, E., Murphy, S. A., Karwatowska-Prokopczuk, E., Buros, J. L., Chaitman, B. R., & Morrow, D. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.037 · Cited by 198
Self-citationEffects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi495 · Cited by 193
Self-citationMorrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., & Braunwald, E. (2009) · Circulation · doi:10.1161/circulationaha.107.763912 · Cited by 170
Self-citationEconomic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial
Arnold, S. V., Morrow, D. A., Lei, Y., Cohen, D. J., Mahoney, E. M., Braunwald, E., & Chan, P. S. (2009) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.829523 · Cited by 128
Ranolazine: Ion‐channel‐blocking actions and in vivo electrophysiological effects
Schram, G., Zhang, L., Derakhchan, K., Ehrlich, J. R., Belardinelli, L., & Nattel, S. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705879 · Cited by 101
“Advance online publication: 26 July 2004 British Journal of Pharmacology (2004) 142, 1300–1308 & 2004 Nature Publishing Group All rights reserved 0007–1188/04 $30.00 www.nature.com/bjp et al., 1992; Pepine & Wolff, 1999; Louis et al., 2002; Chaitman et al., 2004a, b).”
BackgroundInfluentialStrayer, D. R., Carter, W. A., Stouch, B. C., Stevens, S. R., Bateman, L., Cimoch, P. J., Lapp, C. W., Peterson, D. L., the Chronic Fatigue Syndrome AMP-516 Study Group, & Mitchell, W. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031334 · Cited by 84
Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L. (2010) · Diabetes Care · doi:10.2337/dc09-2334 · Cited by 78
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
Szél, T., Koncz, I., Jost, N., Baczkó, I., Husti, Z., Virág, L., Bussek, A., Wettwer, E., Ravens, U., Papp, J. G., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.042 · Cited by 34
Arnold, S. V., McGuire, D. K., Spertus, J. A., Li, Y., Yue, P., Ben-Yehuda, O., Belardinelli, L., Jones, P. G., Olmsted, A., Chaitman, B. R., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.020 · Cited by 19
Self-citationMedical Treatment of Peripheral Artery Disease
Gornik, H. L., & Creager, M. A. (2013) · Vascular Medicine: A Companion to Braunwald's Heart Disease · doi:10.1016/b978-1-4377-2930-6.00019-7 · Cited by 12
Metadata
- Authors
- Chaitman, B. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-01-21
- Volume
- 291
- Issue
- 3
- Pages
- 309
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2049390983
- Cited by
- 681
- References
- 22
- FWCI
- 30.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.